Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полифакториальные эффекты Lactobacillus paracasei DG в регуляции микробно-тканевого комплекса
Полифакториальные эффекты Lactobacillus paracasei DG в регуляции микробно-тканевого комплекса
Захаренко С.М. Полифакториальные эффекты Lactobacillus paracasei DG в регуляции микробно-тканевого комплекса. Терапевтический архив. 2024;96(2):168–175. DOI: 10.26442/00403660.2024.02.202649
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
DOI: 10.26442/00403660.2024.02.202649
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
DOI: 10.26442/00403660.2024.02.202649
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Микробиом кишечника человека представляет собой сложную биологическую систему, функции и метаболические процессы которой являются результатом множественных взаимодействий между микробными группами. Внутри этих групп и между ними формируются специфические взаимосвязи, позволяющие дублировать и резервировать отдельные функции, системно управлять их реализацией и в целом обеспечивать надежное функционирование всего микробиома, в том числе в интересах макроорганизма-хозяина. Решающая роль в функционировании микробиоценоза как цельной системы принадлежит функционально-метаболическому микробному ядру. Современный пробиотик Lactobacillus paracasei DG благодаря природным свойствам выполняет функцию «дирижера» микробиоценоза желудочно-кишечного тракта, регулируя метаболическую активность нормофлоры кишечника, реализуя иммунотропные эффекты благодаря продукции экзополисахаридов, в том числе неизвестного ранее экзополисахарида b, поддерживая целостность кишечного эпителиального барьера, оказывая противовирусное действие, дистантные эффекты в отношении микробиоценозов других экологических ниш.
Ключевые слова: микробиом, Lactobacillus paracasei DG, микробиоценоз-ориентированная терапия, микробно-тканевой комплекс
Keywords: microbiome, Lactobacillus paracasei DG, microbiocenosis-oriented therapy, microbial-tissue complex
Ключевые слова: микробиом, Lactobacillus paracasei DG, микробиоценоз-ориентированная терапия, микробно-тканевой комплекс
________________________________________________
Keywords: microbiome, Lactobacillus paracasei DG, microbiocenosis-oriented therapy, microbial-tissue complex
Полный текст
Список литературы
1. Doré J, Multon MC, Béhier JM; Participants of Giens XXXII, Round Table No 2. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? Therapie. 2017;72(1):21-38. DOI:10.1016/j.therap.2016.12.007
2. Martini E, Krug SM, Siegmund B, et al. Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33-46. DOI:10.1016/j.jcmgh.2017.03.007
3. Венцловайте Н.Д., Горячева Л.Г., Гончар Н.В., и др. Патогенетическая связь между состоянием микробиоты кишечника и заболеваниями печени. Инфекционные болезни: новости, мнения, обучение. 2022;11(2):97-105 [Ventslovayte ND, Goriacheva LG, Gonchar NV, et al. Pathogenetic relationship between the condition gut microbiota and liver diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training. 2022;11(2):97-105 (in Russian)]. DOI:10.33029/2305-3496-2022-11-2-97-105
4. Al-Rashidi HE. Gut microbiota and immunity relevance in eubiosis and dysbiosis. Saudi J Biol Sci. 2022;29(3):1628-43. DOI:10.1016/j.sjbs.2021.10.068
5. Ефремова Н.А., Никифорова А.О., Грешнякова В.А. Изменение состава кишечной микробиоты у пациентов с хроническим гепатитом C, неалкогольной жировой болезнью печени на различных стадиях заболеваний печени. Морская медицина. 2023;9(3):24-39 [Efremova NA, Nikiforova AO, Greshnyakova VA. Changes in the composition of gut microbiota in patients with chronic hepatitis C, non-alcoholic fatty liver disease at different stages of liver disease. Marine Medicine. 2023;9(3):24-39 (in Russian)].
DOI:10.22328/2413-5747-2023-9-3-24-39
6. Stolfi C, Maresca C, Monteleone G, Laudisi F. Implication of intestinal barrier dysfunction in gut dysbiosis and diseases. Biomedicines. 2022;10(2):289. DOI:10.3390/biomedicines10020289
7. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24(6):503-12.
DOI:10.1111/j.1365-2982.2012.01921.x
8. Lechuga S, Ivanov AI. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochim Biophys Acta Mol Cell Res. 2017;1864(7):1183-94. DOI:10.1016/j.bbamcr.2017.03.007
9. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23(4):379-83. DOI:10.1097/MOG.0b013e32816aa392
10. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124(1):3-20; quiz 21-2. DOI:10.1016/j.jaci.2009.05.038
11. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):1-9. DOI:10.1038/s12276-018-0126-x
12. Obrenovich MEM. Leaky gut, leaky brain? Microorganisms. 2018;6(4):107. DOI:10.3390/microorganisms6040107
13. Carloni S, Rescigno M. Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers. Semin Immunopathol. 2022;44(6):869-82. DOI:10.1007/s00281-022-00955-3
14. Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: A focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol. 2021;12:658354. DOI:10.3389/fimmu.2021.658354
15. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. DOI:10.1371/journal.pbio.1002533
16. Masterson D. "Total microbiome company" is bringing microbiome innovation to the masses. 2022. Available at: https://www.nutraingredients-usa.com/Article/2022/09/08/total-microbiome-company-is-bringing-microbi.... Accessed: 16.12.2023.
17. Hugon P, Dufour JC, Colson P, et al. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211-9.
DOI:10.1016/S1473-3099(15)00293-5
18. Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 2017;5(1):153. DOI:10.1186/s40168-017-0373-4
19. Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. DOI:10.3390/microorganisms7010014
20. Flint HJ, Bayer EA, Rincon MT, et al. Polysaccharide utilization by gut bacteria: Potential for new insights from genomic analysis. Nat Rev Microbiol. 2008;6(2):121-31. DOI:10.1038/nrmicro1817
21. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 2016;24(5):402-13. DOI:10.1016/j.tim.2016.02.002
22. Qin J, Li R, Raes J, Arumugam M, et al.; MetaHIT Consortium; Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
23. Forster SC, Kumar N, Anonye BO, et al. A human gut bacterial genome and culture collection for improved metagenomic analyses. Nat Biotechnol. 2019;37(2):186-92. DOI:10.1038/s41587-018-0009-7
24. Zelezniak A, Andrejev S, Ponomarova O, et al. Metabolic dependencies drive species co-occurrence in diverse microbial communities. Proc Natl Acad Sci USA. 2015;112(20):6449-54. DOI:10.1073/pnas.1421834112
25. Hall CV, Lord A, Betzel R, et al. Co-existence of network architectures supporting the human gut microbiome. iScience. 2019;22:380-91. DOI:10.1016/j.isci.2019.11.032
26. Haffner JJ, Katemauswa M, Kagone TS, et al. The core human fecal metabolome. bioRxiv. 2021.05.08.442269. DOI:10.1101/2021.05.08.442269
27. Human Microbiome Market Size & Share, by Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs); Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases); Organism Type (Aerobic Organisms, Obligate & Facultative Anaerobes, Genetically Engineered Strains, BSL-2 & Spore-Forming Species); Application (Therapeutics, Diagnostics) – Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023–2035. Available at: https://www.researchnester.com/reports/human-microbiome-market/4062. Accessed: 16.12.2023.
28. Human Microbiome Market (4th Edition): Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule (Small Molecule and Biologic), Type of Product (Probiotic Drugs and Other Drugs), Target Indication. Industry Trends and Global Forecasts, 2022–2035. Available at: https://www.giiresearch.com/report/root1071905-human-microbiome-market-4th-edition-focus-on.html. Accessed: 16.12.2023.
29. Balzaretti S, Taverniti V, Guglielmetti S, et al. A novel rhamnose-rich hetero-exopolysaccharide isolated from Lactobacillus paracasei DG activates THP-1 human monocytic cells. Appl Environ Microbiol. 2017;83(3):e02702-16. DOI:10.1128/AEM.02702-16
30. Radicioni M, Koirala R, Fiore W, et al. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur J Nutr. 2019;58(8):3161-70. DOI:10.1007/s00394-018-1860-5
31. Arioli S, Koirala R, Taverniti V, et al. Quantitative recovery of viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) after gastrointestinal passage in healthy adults. Front Microbiol. 2018;9:1720. DOI:10.3389/fmicb.2018.01720
32. Altaha BM, Wadi J, Shehabi AA. Detection probiotic's DNA of Lactobacillus paracasei in healthy human faeces. J Pharm Res Int. 2018;23:44636. DOI:10.9734/JPRI/2018/44636
33. Drago L, De Vecchi E, Valli M, Gismondo MR. Colonizzazione intestinale di Lactobacillus casei subsp. casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci e Terapia. 2002;19(1/2):72-6.
34. Ferrario C, Taverniti V, Milani C, et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr. 2014;144(11):1787-96. DOI:10.3945/jn.114.197723
35. Торшин И.Ю., Громова О.А., Максимов В.А., и др. Анализ штамм-специфичных эффектов лактобацилл L. casei DG (L. paracasei CNCM I-1572) и возможность их применения в клинической практике. Экспериментальная и клиническая гастроэнтерология. 2019;162(2):151-8 [Torshin IYu, Gromova OA, Maksimov VA, et al. Analysis of the strain-specific effects of lactobacilli L. casei DG (L. paracasei CNCM I-1572) and the possibility of their use in clinical practice. Experimental and Clinical Gastroenterology. 2019;162(2):151-8 (in Russian)]. DOI:10.31146/1682-8658-ecg-162-2-151-158
36. Taverniti V, Cesari V, Gargari G, et al. Probiotics modulate mouse gut microbiota and influence intestinal immune and serotonergic gene expression in a site-specific fashion. Front Microbiol. 2021;12:706135. DOI:10.3389/fmicb.2021.706135
37. Zambori C, Morvay AA, Sala C, et al. Antimicrobial effect of probiotics on bacterial species from dental plaque. J Infect Dev Ctries. 2016;10(3):214-21. DOI:10.3855/jidc.6800
38. Cremon C, Guglielmetti S, Gargari G, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 2018;6(4):604-13. DOI:10.1177/2050640617736478
39. Хлынов И.Б., Хлынова Р.И., Воронова Е.И., и др. Эффективность и безопасность Lactobacillus paracasei CNCM I-1572 и фруктоолигосахаридов в лечении больных СРК с запором. Экспериментальная и клиническая гастроэнтерология. 2021;190(6):57-62 [Khlinov IB, Khlynova RI, Voronova EI, et al. Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo-oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation. Experimental and Clinical Gastroenterology. 2021;1(6):57-62 (in Russian)]. DOI:10.31146/1682-8658-ecg-190-6-57-62
40. Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: An ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):53. DOI:10.1186/s12876-017-0605-x
41. Turco F, Andreozzi P, Palumbo I, et al. Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of L. casei DG® (Lactobacillus paracasei CNCM I-1572). United European Gastroenterol J. 2017;5(5):715-24. DOI:10.1177/2050640616684398
42. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: A prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40(4):312-6. DOI:10.1097/01.mcg.0000210092.77296.6d
43. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: Mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – A double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38(7):741-51. DOI:10.1111/apt.12463
44. Casula E, Pisano MB, Serreli G, et al. Probiotic lactobacilli attenuate oxysterols-induced alteration of intestinal epithelial cell monolayer permeability: Focus on tight junction modulation. Food Chem Toxicol. 2023;172:113558. DOI:10.1016/j.fct.2022.113558
45. Топчий Т.Б., Ардатская М.Д., Буторова Л.И., и др. Особенности состояния кишечника на фоне новой коронавирусной инфекции. Терапевтический архив. 2022;92(7):920-6 [Topchiy TВ, Ardatskaya MD, Butorova LI, et al. Features of the intestine conditions at patients with a new coronavirus infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(7):920-6 (in Russian)]. DOI:10.26442/00403660.2022.07.201768
46. Ахмедов В.А. Коррекция нарушений микробного состава кишечника как потенциальное звено в комплексной терапии пациентов с COVID-19. Терапевтический архив. 2022;94(2):277-82 [Akhmedov VA. Correction of intestinal microbial composition disturbances as a potential link in complex therapy of patients with COVID-19. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2):277-82 (in Russian)]. DOI:10.26442/00403660.2022.02.201388
47. Паценко М.Б., Ардатская М.Д., Анучкин А.А., и др. Отдаленные последствия COVID-19 у пациентов с функциональными расстройствами кишечника, реабилитационные возможности микробиоценоз-ориентированной терапии. Терапевтический архив. 2023;95(12):1119-27 [Patsenko MB, Ardatskaya MD, Anuchkin AA, et al. Long-term consequences of COVID-19 in patients with functional bowel disorders, rehabilitation prospective of microbiocenosis-oriented therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(12):1119-27 (in Russian)]. DOI:10.26442/00403660.2023.12.202523
48. Salaris C, Scarpa M, Elli M, et al. Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells. Gut Microbes. 2021;13(1):1961970. DOI:10.1080/19490976.2021.1961970
49. Castagliuolo I, Scarpa M, Brun P, et al. Co-administration of vitamin D3 and Lacticaseibacillus paracasei DG increase 25-hydroxyvitamin D serum levels in mice. Ann Microbiol. 2021;71(1):42. DOI:10.1186/s13213-021-01655-3
50. Карахалис Л.Ю., Жигаленко А.Р., Доценко С.В., Воронкова В.В. Подготовка пациенток с хроническим эндометритом к процедуре вспомогательных репродуктивных технологий. Акушерство и гинекология. 2023;12:152-7 [Karakhalis LYu, Zhigalenko AR, Dotsenko SV, Voronkova VV. Preparation of patients with chronic endometritis for the procedure of assisted reproductive technologies. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2023;12:152-7 (in Russian)]. DOI:10.18565/aig.2023.291
51. Cai T, Gallelli L, Cione E, et al. The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: Results from a phase IV study. World J Urol. 2021;39(9):3433-40. DOI:10.1007/s00345-020-03580-7
2. Martini E, Krug SM, Siegmund B, et al. Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33-46. DOI:10.1016/j.jcmgh.2017.03.007
3. Ventslovayte ND, Goriacheva LG, Gonchar NV, et al. Pathogenetic relationship between the condition gut microbiota and liver diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training. 2022;11(2):97-105 (in Russian). DOI:10.33029/2305-3496-2022-11-2-97-105
4. Al-Rashidi HE. Gut microbiota and immunity relevance in eubiosis and dysbiosis. Saudi J Biol Sci. 2022;29(3):1628-43. DOI:10.1016/j.sjbs.2021.10.068
5. Efremova NA, Nikiforova AO, Greshnyakova VA. Changes in the composition of gut microbiota in patients with chronic hepatitis C, non-alcoholic fatty liver disease at different stages of liver disease. Marine Medicine. 2023;9(3):24-39 (in Russian). DOI:10.22328/2413-5747-2023-9-3-24-39
6. Stolfi C, Maresca C, Monteleone G, Laudisi F. Implication of intestinal barrier dysfunction in gut dysbiosis and diseases. Biomedicines. 2022;10(2):289. DOI:10.3390/biomedicines10020289
7. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24(6):503-12.
DOI:10.1111/j.1365-2982.2012.01921.x
8. Lechuga S, Ivanov AI. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochim Biophys Acta Mol Cell Res. 2017;1864(7):1183-94. DOI:10.1016/j.bbamcr.2017.03.007
9. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23(4):379-83. DOI:10.1097/MOG.0b013e32816aa392
10. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124(1):3-20; quiz 21-2. DOI:10.1016/j.jaci.2009.05.038
11. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):1-9. DOI:10.1038/s12276-018-0126-x
12. Obrenovich MEM. Leaky gut, leaky brain? Microorganisms. 2018;6(4):107. DOI:10.3390/microorganisms6040107
13. Carloni S, Rescigno M. Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers. Semin Immunopathol. 2022;44(6):869-82. DOI:10.1007/s00281-022-00955-3
14. Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: A focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol. 2021;12:658354. DOI:10.3389/fimmu.2021.658354
15. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. DOI:10.1371/journal.pbio.1002533
16. Masterson D. "Total microbiome company" is bringing microbiome innovation to the masses. 2022. Available at: https://www.nutraingredients-usa.com/Article/2022/09/08/total-microbiome-company-is-bringing-microbi.... Accessed: 16.12.2023.
17. Hugon P, Dufour JC, Colson P, et al. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211-9.
DOI:10.1016/S1473-3099(15)00293-5
18. Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 2017;5(1):153. DOI:10.1186/s40168-017-0373-4
19. Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. DOI:10.3390/microorganisms7010014
20. Flint HJ, Bayer EA, Rincon MT, et al. Polysaccharide utilization by gut bacteria: Potential for new insights from genomic analysis. Nat Rev Microbiol. 2008;6(2):121-31. DOI:10.1038/nrmicro1817
21. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 2016;24(5):402-13. DOI:10.1016/j.tim.2016.02.002
22. Qin J, Li R, Raes J, Arumugam M, et al.; MetaHIT Consortium; Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
23. Forster SC, Kumar N, Anonye BO, et al. A human gut bacterial genome and culture collection for improved metagenomic analyses. Nat Biotechnol. 2019;37(2):186-92. DOI:10.1038/s41587-018-0009-7
24. Zelezniak A, Andrejev S, Ponomarova O, et al. Metabolic dependencies drive species co-occurrence in diverse microbial communities. Proc Natl Acad Sci USA. 2015;112(20):6449-54. DOI:10.1073/pnas.1421834112
25. Hall CV, Lord A, Betzel R, et al. Co-existence of network architectures supporting the human gut microbiome. iScience. 2019;22:380-91. DOI:10.1016/j.isci.2019.11.032
26. Haffner JJ, Katemauswa M, Kagone TS, et al. The core human fecal metabolome. bioRxiv. 2021.05.08.442269. DOI:10.1101/2021.05.08.442269
27. Human Microbiome Market Size & Share, by Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs); Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases); Organism Type (Aerobic Organisms, Obligate & Facultative Anaerobes, Genetically Engineered Strains, BSL-2 & Spore-Forming Species); Application (Therapeutics, Diagnostics) – Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023–2035. Available at: https://www.researchnester.com/reports/human-microbiome-market/4062. Accessed: 16.12.2023.
28. Human Microbiome Market (4th Edition): Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule (Small Molecule and Biologic), Type of Product (Probiotic Drugs and Other Drugs), Target Indication. Industry Trends and Global Forecasts, 2022–2035. Available at: https://www.giiresearch.com/report/root1071905-human-microbiome-market-4th-edition-focus-on.html. Accessed: 16.12.2023.
29. Balzaretti S, Taverniti V, Guglielmetti S, et al. A novel rhamnose-rich hetero-exopolysaccharide isolated from Lactobacillus paracasei DG activates THP-1 human monocytic cells. Appl Environ Microbiol. 2017;83(3):e02702-16. DOI:10.1128/AEM.02702-16
30. Radicioni M, Koirala R, Fiore W, et al. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur J Nutr. 2019;58(8):3161-70. DOI:10.1007/s00394-018-1860-5
31. Arioli S, Koirala R, Taverniti V, et al. Quantitative recovery of viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) after gastrointestinal passage in healthy adults. Front Microbiol. 2018;9:1720. DOI:10.3389/fmicb.2018.01720
32. Altaha BM, Wadi J, Shehabi AA. Detection probiotic's DNA of Lactobacillus paracasei in healthy human faeces. J Pharm Res Int. 2018;23:44636. DOI:10.9734/JPRI/2018/44636
33. Drago L, De Vecchi E, Valli M, Gismondo MR. Colonizzazione intestinale di Lactobacillus casei subsp. casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci e Terapia. 2002;19(1/2):72-6.
34. Ferrario C, Taverniti V, Milani C, et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr. 2014;144(11):1787-96. DOI:10.3945/jn.114.197723
35. Torshin IYu, Gromova OA, Maksimov VA, et al. Analysis of the strain-specific effects of lactobacilli L. casei DG (L. paracasei CNCM I-1572) and the possibility of their use in clinical practice. Experimental and Clinical Gastroenterology. 2019;162(2):151-8 (in Russian). DOI:10.31146/1682-8658-ecg-162-2-151-158
36. Taverniti V, Cesari V, Gargari G, et al. Probiotics modulate mouse gut microbiota and influence intestinal immune and serotonergic gene expression in a site-specific fashion. Front Microbiol. 2021;12:706135. DOI:10.3389/fmicb.2021.706135
37. Zambori C, Morvay AA, Sala C, et al. Antimicrobial effect of probiotics on bacterial species from dental plaque. J Infect Dev Ctries. 2016;10(3):214-21. DOI:10.3855/jidc.6800
38. Cremon C, Guglielmetti S, Gargari G, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 2018;6(4):604-13. DOI:10.1177/2050640617736478
39. Khlinov IB, Khlynova RI, Voronova EI, et al. Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo-oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation. Experimental and Clinical Gastroenterology. 2021;1(6):57-62 (in Russian). DOI:10.31146/1682-8658-ecg-190-6-57-62
40. Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: An ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):53. DOI:10.1186/s12876-017-0605-x
41. Turco F, Andreozzi P, Palumbo I, et al. Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of L. casei DG® (Lactobacillus paracasei CNCM I-1572). United European Gastroenterol J. 2017;5(5):715-24. DOI:10.1177/2050640616684398
42. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: A prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40(4):312-6. DOI:10.1097/01.mcg.0000210092.77296.6d
43. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: Mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – A double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38(7):741-51. DOI:10.1111/apt.12463
44. Casula E, Pisano MB, Serreli G, et al. Probiotic lactobacilli attenuate oxysterols-induced alteration of intestinal epithelial cell monolayer permeability: Focus on tight junction modulation. Food Chem Toxicol. 2023;172:113558. DOI:10.1016/j.fct.2022.113558
45. Topchiy TВ, Ardatskaya MD, Butorova LI, et al. Features of the intestine conditions at patients with a new coronavirus infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(7):920-6 (in Russian). DOI:10.26442/00403660.2022.07.201768
46. Akhmedov VA. Correction of intestinal microbial composition disturbances as a potential link in complex therapy of patients with COVID-19. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2):277-82 (in Russian). DOI:10.26442/00403660.2022.02.201388
47. Patsenko MB, Ardatskaya MD, Anuchkin AA, et al. Long-term consequences of COVID-19 in patients with functional bowel disorders, rehabilitation prospective of microbiocenosis-oriented therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(12):1119-27 (in Russian). DOI:10.26442/00403660.2023.12.202523
48. Salaris C, Scarpa M, Elli M, et al. Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells. Gut Microbes. 2021;13(1):1961970. DOI:10.1080/19490976.2021.1961970
49. Castagliuolo I, Scarpa M, Brun P, et al. Co-administration of vitamin D3 and Lacticaseibacillus paracasei DG increase 25-hydroxyvitamin D serum levels in mice. Ann Microbiol. 2021;71(1):42. DOI:10.1186/s13213-021-01655-3
50. Karakhalis LYu, Zhigalenko AR, Dotsenko SV, Voronkova VV. Preparation of patients with chronic endometritis for the procedure of assisted reproductive technologies. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2023;12:152-7 (in Russian). DOI:10.18565/aig.2023.291
51. Cai T, Gallelli L, Cione E, et al. The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: Results from a phase IV study. World J Urol. 2021;39(9):3433-40. DOI:10.1007/s00345-020-03580-7
2. Martini E, Krug SM, Siegmund B, et al. Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33-46. DOI:10.1016/j.jcmgh.2017.03.007
3. Венцловайте Н.Д., Горячева Л.Г., Гончар Н.В., и др. Патогенетическая связь между состоянием микробиоты кишечника и заболеваниями печени. Инфекционные болезни: новости, мнения, обучение. 2022;11(2):97-105 [Ventslovayte ND, Goriacheva LG, Gonchar NV, et al. Pathogenetic relationship between the condition gut microbiota and liver diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training. 2022;11(2):97-105 (in Russian)]. DOI:10.33029/2305-3496-2022-11-2-97-105
4. Al-Rashidi HE. Gut microbiota and immunity relevance in eubiosis and dysbiosis. Saudi J Biol Sci. 2022;29(3):1628-43. DOI:10.1016/j.sjbs.2021.10.068
5. Ефремова Н.А., Никифорова А.О., Грешнякова В.А. Изменение состава кишечной микробиоты у пациентов с хроническим гепатитом C, неалкогольной жировой болезнью печени на различных стадиях заболеваний печени. Морская медицина. 2023;9(3):24-39 [Efremova NA, Nikiforova AO, Greshnyakova VA. Changes in the composition of gut microbiota in patients with chronic hepatitis C, non-alcoholic fatty liver disease at different stages of liver disease. Marine Medicine. 2023;9(3):24-39 (in Russian)].
DOI:10.22328/2413-5747-2023-9-3-24-39
6. Stolfi C, Maresca C, Monteleone G, Laudisi F. Implication of intestinal barrier dysfunction in gut dysbiosis and diseases. Biomedicines. 2022;10(2):289. DOI:10.3390/biomedicines10020289
7. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24(6):503-12.
DOI:10.1111/j.1365-2982.2012.01921.x
8. Lechuga S, Ivanov AI. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochim Biophys Acta Mol Cell Res. 2017;1864(7):1183-94. DOI:10.1016/j.bbamcr.2017.03.007
9. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23(4):379-83. DOI:10.1097/MOG.0b013e32816aa392
10. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124(1):3-20; quiz 21-2. DOI:10.1016/j.jaci.2009.05.038
11. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):1-9. DOI:10.1038/s12276-018-0126-x
12. Obrenovich MEM. Leaky gut, leaky brain? Microorganisms. 2018;6(4):107. DOI:10.3390/microorganisms6040107
13. Carloni S, Rescigno M. Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers. Semin Immunopathol. 2022;44(6):869-82. DOI:10.1007/s00281-022-00955-3
14. Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: A focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol. 2021;12:658354. DOI:10.3389/fimmu.2021.658354
15. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. DOI:10.1371/journal.pbio.1002533
16. Masterson D. "Total microbiome company" is bringing microbiome innovation to the masses. 2022. Available at: https://www.nutraingredients-usa.com/Article/2022/09/08/total-microbiome-company-is-bringing-microbi.... Accessed: 16.12.2023.
17. Hugon P, Dufour JC, Colson P, et al. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211-9.
DOI:10.1016/S1473-3099(15)00293-5
18. Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 2017;5(1):153. DOI:10.1186/s40168-017-0373-4
19. Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. DOI:10.3390/microorganisms7010014
20. Flint HJ, Bayer EA, Rincon MT, et al. Polysaccharide utilization by gut bacteria: Potential for new insights from genomic analysis. Nat Rev Microbiol. 2008;6(2):121-31. DOI:10.1038/nrmicro1817
21. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 2016;24(5):402-13. DOI:10.1016/j.tim.2016.02.002
22. Qin J, Li R, Raes J, Arumugam M, et al.; MetaHIT Consortium; Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
23. Forster SC, Kumar N, Anonye BO, et al. A human gut bacterial genome and culture collection for improved metagenomic analyses. Nat Biotechnol. 2019;37(2):186-92. DOI:10.1038/s41587-018-0009-7
24. Zelezniak A, Andrejev S, Ponomarova O, et al. Metabolic dependencies drive species co-occurrence in diverse microbial communities. Proc Natl Acad Sci USA. 2015;112(20):6449-54. DOI:10.1073/pnas.1421834112
25. Hall CV, Lord A, Betzel R, et al. Co-existence of network architectures supporting the human gut microbiome. iScience. 2019;22:380-91. DOI:10.1016/j.isci.2019.11.032
26. Haffner JJ, Katemauswa M, Kagone TS, et al. The core human fecal metabolome. bioRxiv. 2021.05.08.442269. DOI:10.1101/2021.05.08.442269
27. Human Microbiome Market Size & Share, by Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs); Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases); Organism Type (Aerobic Organisms, Obligate & Facultative Anaerobes, Genetically Engineered Strains, BSL-2 & Spore-Forming Species); Application (Therapeutics, Diagnostics) – Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023–2035. Available at: https://www.researchnester.com/reports/human-microbiome-market/4062. Accessed: 16.12.2023.
28. Human Microbiome Market (4th Edition): Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule (Small Molecule and Biologic), Type of Product (Probiotic Drugs and Other Drugs), Target Indication. Industry Trends and Global Forecasts, 2022–2035. Available at: https://www.giiresearch.com/report/root1071905-human-microbiome-market-4th-edition-focus-on.html. Accessed: 16.12.2023.
29. Balzaretti S, Taverniti V, Guglielmetti S, et al. A novel rhamnose-rich hetero-exopolysaccharide isolated from Lactobacillus paracasei DG activates THP-1 human monocytic cells. Appl Environ Microbiol. 2017;83(3):e02702-16. DOI:10.1128/AEM.02702-16
30. Radicioni M, Koirala R, Fiore W, et al. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur J Nutr. 2019;58(8):3161-70. DOI:10.1007/s00394-018-1860-5
31. Arioli S, Koirala R, Taverniti V, et al. Quantitative recovery of viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) after gastrointestinal passage in healthy adults. Front Microbiol. 2018;9:1720. DOI:10.3389/fmicb.2018.01720
32. Altaha BM, Wadi J, Shehabi AA. Detection probiotic's DNA of Lactobacillus paracasei in healthy human faeces. J Pharm Res Int. 2018;23:44636. DOI:10.9734/JPRI/2018/44636
33. Drago L, De Vecchi E, Valli M, Gismondo MR. Colonizzazione intestinale di Lactobacillus casei subsp. casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci e Terapia. 2002;19(1/2):72-6.
34. Ferrario C, Taverniti V, Milani C, et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr. 2014;144(11):1787-96. DOI:10.3945/jn.114.197723
35. Торшин И.Ю., Громова О.А., Максимов В.А., и др. Анализ штамм-специфичных эффектов лактобацилл L. casei DG (L. paracasei CNCM I-1572) и возможность их применения в клинической практике. Экспериментальная и клиническая гастроэнтерология. 2019;162(2):151-8 [Torshin IYu, Gromova OA, Maksimov VA, et al. Analysis of the strain-specific effects of lactobacilli L. casei DG (L. paracasei CNCM I-1572) and the possibility of their use in clinical practice. Experimental and Clinical Gastroenterology. 2019;162(2):151-8 (in Russian)]. DOI:10.31146/1682-8658-ecg-162-2-151-158
36. Taverniti V, Cesari V, Gargari G, et al. Probiotics modulate mouse gut microbiota and influence intestinal immune and serotonergic gene expression in a site-specific fashion. Front Microbiol. 2021;12:706135. DOI:10.3389/fmicb.2021.706135
37. Zambori C, Morvay AA, Sala C, et al. Antimicrobial effect of probiotics on bacterial species from dental plaque. J Infect Dev Ctries. 2016;10(3):214-21. DOI:10.3855/jidc.6800
38. Cremon C, Guglielmetti S, Gargari G, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 2018;6(4):604-13. DOI:10.1177/2050640617736478
39. Хлынов И.Б., Хлынова Р.И., Воронова Е.И., и др. Эффективность и безопасность Lactobacillus paracasei CNCM I-1572 и фруктоолигосахаридов в лечении больных СРК с запором. Экспериментальная и клиническая гастроэнтерология. 2021;190(6):57-62 [Khlinov IB, Khlynova RI, Voronova EI, et al. Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo-oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation. Experimental and Clinical Gastroenterology. 2021;1(6):57-62 (in Russian)]. DOI:10.31146/1682-8658-ecg-190-6-57-62
40. Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: An ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):53. DOI:10.1186/s12876-017-0605-x
41. Turco F, Andreozzi P, Palumbo I, et al. Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of L. casei DG® (Lactobacillus paracasei CNCM I-1572). United European Gastroenterol J. 2017;5(5):715-24. DOI:10.1177/2050640616684398
42. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: A prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40(4):312-6. DOI:10.1097/01.mcg.0000210092.77296.6d
43. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: Mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – A double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38(7):741-51. DOI:10.1111/apt.12463
44. Casula E, Pisano MB, Serreli G, et al. Probiotic lactobacilli attenuate oxysterols-induced alteration of intestinal epithelial cell monolayer permeability: Focus on tight junction modulation. Food Chem Toxicol. 2023;172:113558. DOI:10.1016/j.fct.2022.113558
45. Топчий Т.Б., Ардатская М.Д., Буторова Л.И., и др. Особенности состояния кишечника на фоне новой коронавирусной инфекции. Терапевтический архив. 2022;92(7):920-6 [Topchiy TВ, Ardatskaya MD, Butorova LI, et al. Features of the intestine conditions at patients with a new coronavirus infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(7):920-6 (in Russian)]. DOI:10.26442/00403660.2022.07.201768
46. Ахмедов В.А. Коррекция нарушений микробного состава кишечника как потенциальное звено в комплексной терапии пациентов с COVID-19. Терапевтический архив. 2022;94(2):277-82 [Akhmedov VA. Correction of intestinal microbial composition disturbances as a potential link in complex therapy of patients with COVID-19. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2):277-82 (in Russian)]. DOI:10.26442/00403660.2022.02.201388
47. Паценко М.Б., Ардатская М.Д., Анучкин А.А., и др. Отдаленные последствия COVID-19 у пациентов с функциональными расстройствами кишечника, реабилитационные возможности микробиоценоз-ориентированной терапии. Терапевтический архив. 2023;95(12):1119-27 [Patsenko MB, Ardatskaya MD, Anuchkin AA, et al. Long-term consequences of COVID-19 in patients with functional bowel disorders, rehabilitation prospective of microbiocenosis-oriented therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(12):1119-27 (in Russian)]. DOI:10.26442/00403660.2023.12.202523
48. Salaris C, Scarpa M, Elli M, et al. Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells. Gut Microbes. 2021;13(1):1961970. DOI:10.1080/19490976.2021.1961970
49. Castagliuolo I, Scarpa M, Brun P, et al. Co-administration of vitamin D3 and Lacticaseibacillus paracasei DG increase 25-hydroxyvitamin D serum levels in mice. Ann Microbiol. 2021;71(1):42. DOI:10.1186/s13213-021-01655-3
50. Карахалис Л.Ю., Жигаленко А.Р., Доценко С.В., Воронкова В.В. Подготовка пациенток с хроническим эндометритом к процедуре вспомогательных репродуктивных технологий. Акушерство и гинекология. 2023;12:152-7 [Karakhalis LYu, Zhigalenko AR, Dotsenko SV, Voronkova VV. Preparation of patients with chronic endometritis for the procedure of assisted reproductive technologies. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2023;12:152-7 (in Russian)]. DOI:10.18565/aig.2023.291
51. Cai T, Gallelli L, Cione E, et al. The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: Results from a phase IV study. World J Urol. 2021;39(9):3433-40. DOI:10.1007/s00345-020-03580-7
________________________________________________
2. Martini E, Krug SM, Siegmund B, et al. Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33-46. DOI:10.1016/j.jcmgh.2017.03.007
3. Ventslovayte ND, Goriacheva LG, Gonchar NV, et al. Pathogenetic relationship between the condition gut microbiota and liver diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training. 2022;11(2):97-105 (in Russian). DOI:10.33029/2305-3496-2022-11-2-97-105
4. Al-Rashidi HE. Gut microbiota and immunity relevance in eubiosis and dysbiosis. Saudi J Biol Sci. 2022;29(3):1628-43. DOI:10.1016/j.sjbs.2021.10.068
5. Efremova NA, Nikiforova AO, Greshnyakova VA. Changes in the composition of gut microbiota in patients with chronic hepatitis C, non-alcoholic fatty liver disease at different stages of liver disease. Marine Medicine. 2023;9(3):24-39 (in Russian). DOI:10.22328/2413-5747-2023-9-3-24-39
6. Stolfi C, Maresca C, Monteleone G, Laudisi F. Implication of intestinal barrier dysfunction in gut dysbiosis and diseases. Biomedicines. 2022;10(2):289. DOI:10.3390/biomedicines10020289
7. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24(6):503-12.
DOI:10.1111/j.1365-2982.2012.01921.x
8. Lechuga S, Ivanov AI. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochim Biophys Acta Mol Cell Res. 2017;1864(7):1183-94. DOI:10.1016/j.bbamcr.2017.03.007
9. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23(4):379-83. DOI:10.1097/MOG.0b013e32816aa392
10. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124(1):3-20; quiz 21-2. DOI:10.1016/j.jaci.2009.05.038
11. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):1-9. DOI:10.1038/s12276-018-0126-x
12. Obrenovich MEM. Leaky gut, leaky brain? Microorganisms. 2018;6(4):107. DOI:10.3390/microorganisms6040107
13. Carloni S, Rescigno M. Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers. Semin Immunopathol. 2022;44(6):869-82. DOI:10.1007/s00281-022-00955-3
14. Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: A focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol. 2021;12:658354. DOI:10.3389/fimmu.2021.658354
15. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. DOI:10.1371/journal.pbio.1002533
16. Masterson D. "Total microbiome company" is bringing microbiome innovation to the masses. 2022. Available at: https://www.nutraingredients-usa.com/Article/2022/09/08/total-microbiome-company-is-bringing-microbi.... Accessed: 16.12.2023.
17. Hugon P, Dufour JC, Colson P, et al. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211-9.
DOI:10.1016/S1473-3099(15)00293-5
18. Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 2017;5(1):153. DOI:10.1186/s40168-017-0373-4
19. Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. DOI:10.3390/microorganisms7010014
20. Flint HJ, Bayer EA, Rincon MT, et al. Polysaccharide utilization by gut bacteria: Potential for new insights from genomic analysis. Nat Rev Microbiol. 2008;6(2):121-31. DOI:10.1038/nrmicro1817
21. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 2016;24(5):402-13. DOI:10.1016/j.tim.2016.02.002
22. Qin J, Li R, Raes J, Arumugam M, et al.; MetaHIT Consortium; Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
23. Forster SC, Kumar N, Anonye BO, et al. A human gut bacterial genome and culture collection for improved metagenomic analyses. Nat Biotechnol. 2019;37(2):186-92. DOI:10.1038/s41587-018-0009-7
24. Zelezniak A, Andrejev S, Ponomarova O, et al. Metabolic dependencies drive species co-occurrence in diverse microbial communities. Proc Natl Acad Sci USA. 2015;112(20):6449-54. DOI:10.1073/pnas.1421834112
25. Hall CV, Lord A, Betzel R, et al. Co-existence of network architectures supporting the human gut microbiome. iScience. 2019;22:380-91. DOI:10.1016/j.isci.2019.11.032
26. Haffner JJ, Katemauswa M, Kagone TS, et al. The core human fecal metabolome. bioRxiv. 2021.05.08.442269. DOI:10.1101/2021.05.08.442269
27. Human Microbiome Market Size & Share, by Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs); Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases); Organism Type (Aerobic Organisms, Obligate & Facultative Anaerobes, Genetically Engineered Strains, BSL-2 & Spore-Forming Species); Application (Therapeutics, Diagnostics) – Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023–2035. Available at: https://www.researchnester.com/reports/human-microbiome-market/4062. Accessed: 16.12.2023.
28. Human Microbiome Market (4th Edition): Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule (Small Molecule and Biologic), Type of Product (Probiotic Drugs and Other Drugs), Target Indication. Industry Trends and Global Forecasts, 2022–2035. Available at: https://www.giiresearch.com/report/root1071905-human-microbiome-market-4th-edition-focus-on.html. Accessed: 16.12.2023.
29. Balzaretti S, Taverniti V, Guglielmetti S, et al. A novel rhamnose-rich hetero-exopolysaccharide isolated from Lactobacillus paracasei DG activates THP-1 human monocytic cells. Appl Environ Microbiol. 2017;83(3):e02702-16. DOI:10.1128/AEM.02702-16
30. Radicioni M, Koirala R, Fiore W, et al. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur J Nutr. 2019;58(8):3161-70. DOI:10.1007/s00394-018-1860-5
31. Arioli S, Koirala R, Taverniti V, et al. Quantitative recovery of viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) after gastrointestinal passage in healthy adults. Front Microbiol. 2018;9:1720. DOI:10.3389/fmicb.2018.01720
32. Altaha BM, Wadi J, Shehabi AA. Detection probiotic's DNA of Lactobacillus paracasei in healthy human faeces. J Pharm Res Int. 2018;23:44636. DOI:10.9734/JPRI/2018/44636
33. Drago L, De Vecchi E, Valli M, Gismondo MR. Colonizzazione intestinale di Lactobacillus casei subsp. casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci e Terapia. 2002;19(1/2):72-6.
34. Ferrario C, Taverniti V, Milani C, et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr. 2014;144(11):1787-96. DOI:10.3945/jn.114.197723
35. Torshin IYu, Gromova OA, Maksimov VA, et al. Analysis of the strain-specific effects of lactobacilli L. casei DG (L. paracasei CNCM I-1572) and the possibility of their use in clinical practice. Experimental and Clinical Gastroenterology. 2019;162(2):151-8 (in Russian). DOI:10.31146/1682-8658-ecg-162-2-151-158
36. Taverniti V, Cesari V, Gargari G, et al. Probiotics modulate mouse gut microbiota and influence intestinal immune and serotonergic gene expression in a site-specific fashion. Front Microbiol. 2021;12:706135. DOI:10.3389/fmicb.2021.706135
37. Zambori C, Morvay AA, Sala C, et al. Antimicrobial effect of probiotics on bacterial species from dental plaque. J Infect Dev Ctries. 2016;10(3):214-21. DOI:10.3855/jidc.6800
38. Cremon C, Guglielmetti S, Gargari G, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J. 2018;6(4):604-13. DOI:10.1177/2050640617736478
39. Khlinov IB, Khlynova RI, Voronova EI, et al. Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo-oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation. Experimental and Clinical Gastroenterology. 2021;1(6):57-62 (in Russian). DOI:10.31146/1682-8658-ecg-190-6-57-62
40. Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: An ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):53. DOI:10.1186/s12876-017-0605-x
41. Turco F, Andreozzi P, Palumbo I, et al. Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of L. casei DG® (Lactobacillus paracasei CNCM I-1572). United European Gastroenterol J. 2017;5(5):715-24. DOI:10.1177/2050640616684398
42. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: A prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40(4):312-6. DOI:10.1097/01.mcg.0000210092.77296.6d
43. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: Mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – A double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38(7):741-51. DOI:10.1111/apt.12463
44. Casula E, Pisano MB, Serreli G, et al. Probiotic lactobacilli attenuate oxysterols-induced alteration of intestinal epithelial cell monolayer permeability: Focus on tight junction modulation. Food Chem Toxicol. 2023;172:113558. DOI:10.1016/j.fct.2022.113558
45. Topchiy TВ, Ardatskaya MD, Butorova LI, et al. Features of the intestine conditions at patients with a new coronavirus infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(7):920-6 (in Russian). DOI:10.26442/00403660.2022.07.201768
46. Akhmedov VA. Correction of intestinal microbial composition disturbances as a potential link in complex therapy of patients with COVID-19. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2):277-82 (in Russian). DOI:10.26442/00403660.2022.02.201388
47. Patsenko MB, Ardatskaya MD, Anuchkin AA, et al. Long-term consequences of COVID-19 in patients with functional bowel disorders, rehabilitation prospective of microbiocenosis-oriented therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(12):1119-27 (in Russian). DOI:10.26442/00403660.2023.12.202523
48. Salaris C, Scarpa M, Elli M, et al. Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells. Gut Microbes. 2021;13(1):1961970. DOI:10.1080/19490976.2021.1961970
49. Castagliuolo I, Scarpa M, Brun P, et al. Co-administration of vitamin D3 and Lacticaseibacillus paracasei DG increase 25-hydroxyvitamin D serum levels in mice. Ann Microbiol. 2021;71(1):42. DOI:10.1186/s13213-021-01655-3
50. Karakhalis LYu, Zhigalenko AR, Dotsenko SV, Voronkova VV. Preparation of patients with chronic endometritis for the procedure of assisted reproductive technologies. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2023;12:152-7 (in Russian). DOI:10.18565/aig.2023.291
51. Cai T, Gallelli L, Cione E, et al. The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: Results from a phase IV study. World J Urol. 2021;39(9):3433-40. DOI:10.1007/s00345-020-03580-7
Авторы
С.М. Захаренко*
ФГБУ «Детский научно-клинический центр по инфекционным болезням» ФМБА России, Санкт-Петербург, Россия
*zaharenko.sm@niidi.ru
Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases, Saint Petersburg, Russia
*zaharenko.sm@niidi.ru
ФГБУ «Детский научно-клинический центр по инфекционным болезням» ФМБА России, Санкт-Петербург, Россия
*zaharenko.sm@niidi.ru
________________________________________________
Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases, Saint Petersburg, Russia
*zaharenko.sm@niidi.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.